[1]张吉辉,任明.肌腱蛋白C 与心血管疾病[J].国际心血管病杂志,2022,06:351-353.
点击复制
肌腱蛋白C 与心血管疾病(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年06期
- 页码:
- 351-353
- 栏目:
- 综述
- 出版日期:
- 2022-12-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.06.009
- 文献标识码:
- -
- 摘要:
- 肌腱蛋白C（TNC）能够促进促炎性因子释放，介导炎性反应发生，参与多种心 血管疾病的发生发展。该文介绍将TNC 与动脉粥样硬化、心肌梗死、心肌炎、高血压心肌 纤维化、心力衰竭的关系，以期为临床干预提供新思路。
- Abstract:
- -
参考文献/References
[1] World Health Organistion. The top 10causes of death [EB/
OL]
[2022-10-17]. http://www.who.int/mediacentre/factsheets/
fs310/en.
[2] Matsumoto KI, Aoki H. The roles of tenascins in
cardiovascular, inflammatory, and heritable connective tissue
diseases[J]. Front Immunol, 2020, 11:609752.
[3] Chiquet M. Tenascin-C: from discovery to structure-function
relationships[J]. Front Immunol, 2020, 11:611789.
[4] Sakakura T. Serendipity; close encounter of Tenascin C[J].
Front Immunol. 2021, 11:620182.
[5] Albacete-Albacete L, Sánchez-?lvarez M, Del Pozo MA.Extracellular vesicles: an emerging mechanism governing
the secretion and biological roles of Tenascin-C[J]. Front
Immunol, 2021, 12:671485.
[6] Imanaka-Yoshida K. Tenascin-C in heart diseases—the role of
inflammation[J]. Int J Mol Sci, 2021, 22(11):5828.
[7] Jin L, Hastings NE, Blackman BR, et al. Mechanical properties
of the extracellular matrix alter expression of smooth muscle
protein LPP and its partner palladin; relationship to early
atherosclerosis and vascular injury[J]. J Muscle Res Cell
Motil, 2009, 30(1/2):41-55.
[8] 黄君文，李燕，宋佳成，等．肌腱蛋白C和基质金属蛋白
酶9及转化生长因子β1与小鼠主动脉斑块的关系[J]．中华
老年心脑血管病杂志，2018，20(2):191-195．
[9] Li Y, Liu J, Huang JW, et al. In vivo MRI detection of
atherosclerosis in ApoE-deficient mice by using tenascin-Ctargeted
USPIO[J]. Acta Radiol, 2018, 59(12):1431-1437.
[10] Yonebayashi S, Tajiri K, Hara M, et al. Generation of
transgenic mice that conditionally overexpress Tenascin-C[J].
Front Immunol. 2021, 12:620541.
[11] Gao W, Li J, Ni H, et al. Tenascin C: a potential biomarker
for predicting the severity of coronary atherosclerosis[J]. J
Atheroscler Thromb, 2019, 26(1):31-38.
[12] Mehri H, Aslanabadi N, Nourazarian A, et al. Evaluation of
the serum levels of Mannose binding lectin-2, tenascin-C,
and total antioxidant capacity in patients with coronary artery
disease[J]. J Clin Lab Anal, 2021, 35(10):e23967.
[13] 宋佳成，李燕，孟欢，等．肌腱蛋白C在急性心肌梗死中
的表达及磁共振靶向成像的体内实验研究[J]．中华老年心
脑血管病杂志，2016，18(1):71-76．
[14] Gellen B, Thorin-Trescases N, Thorin E, et al. Serum
tenascin-C is independently associated with increased major
adverse cardiovascular events and death in individuals with
type 2 diabetes: a French prospective cohort[J]. Diabetologia,
2020, 63(5):915-923.
[15] Tajiri K, Ieda M. Cardiac complications in immune checkpoint
inhibition therapy[J]. Front Cardiovasc Med, 2019, 6:3.
[16] Siripanthong B, Nazarian S, Muser D, et al. Recognizing
COVID-19-related myocarditis: the possible pathophysiology
and proposed guideline for diagnosis and management[J].
Heart Rhythm, 2020, 17(9):1463-1471.
[17] Mills JT, Schwenzer A, Marsh EK, et al. Airway epithelial
cells generate pro-inflammatory Tenascin-C and small
extracellular vesicles in response to TLR3 stimuli and
rhinovirus infection[J]. Front Immunol, 2019, 10:1987.
[18] Wang J, Han B. Dysregulated CD4+ T cells and microRNAs
in myocarditis[J]. Front Immunol, 2020, 11:539.
[19] Tajiri K, Yonebayashi S, Li S, et al. Immunomodulatory
role of Tenascin-C in myocarditis and inflammatory
cardiomyopathy[J]. Front Immunol, 2021, 12:624703.
[20] Maqbool A, Spary EJ, Manfield IW, et al. Tenascin C
upregulates interleukin-6 expression in human cardiac
myofibroblasts via toll-like receptor 4[J]. World J Cardiol,
2016, 8(5):340-350.
[21] Pistulli R, Andreas E, K?nig S, et al. Characterization of
dendritic cells in human and experimental myocarditis[J]. ESC
Heart Fail, 2020, 7(5):2305-2317.
[22] Tajiri K, Imanaka-Yoshida K, Tsujimura Y, et al. A new mouse
model of chronic myocarditis induced by recombinant bacille
calmette–guèrin expressing a T-cell epitope of cardiac myosin
heavy chain-α[J]. Int J Mol Sci, 2021, 22(2):794.
[23] Podesser BK, Kreibich M, Dzilic E, et al. Tenascin-C promotes
chronic pressure overload-induced cardiac dysfunction,
hypertrophy and myocardial fibrosis[J]. J Hypertens, 2018,
36(4):847-856.
[24] Song L, Wang L, Li F, et al. Bone marrow-derived Tenascin-C
attenuates cardiac hypertrophy by controlling inflammation[J].
J Am Coll Cardiol, 2017, 70(13):1601-1615.
[25] Shimojo N, Hashizume R, Kanayama K, et al. Tenascin-C
may accelerate cardiac fibrosis by activating macrophages via
the integrin αVβ3/nuclear factor-κB/interleukin-6 axis[J].
Hypertension, 2015, 66(4):757-766.
[26] Perera-Gonzalez M, Kiss A, Kaiser P, et al. The role of
tenascin C in cardiac reverse remodeling following bandingdebanding
of the ascending aorta[J]. Int J Mol Sci, 2021,
22(4):2023.
[27] Abbadi D, Laroumanie F, Bizou M, et al. Local production
of tenascin-C acts as a trigger for monocyte/macrophage
recruitment that provokes cardiac dysfunction[J]. Cardiovasc
Res, 2018, 114(1):123-137.
[28] Santer D, Nagel F, Gon?alves IF, et al. Tenascin-C aggravates
ventricular dilatation and angiotensin-converting enzyme
activity after myocardial infarction in mice[J]. ESC Heart Fail,
2020, 7(5):2113-2122.
[29] Kanagala P, Arnold JR, Khan JN, et al. Plasma Tenascin-C: a
prognostic biomarker in heart failure with preserved ejection
fraction[J]. Biomarkers, 2020, 25(7):556-565.
备注/Memo
- 备注/Memo:
-
基金项目：青海省心血管疾病临床医学研究中心项目(2019-SF-L2)
通信作者：任明，E-mail：1104234597@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed139
- 全文下载/Downloads390
- 评论/Comments
